ITeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Simply Wall StNov 15 21:35

ITeos Therapeutics Analyst Ratings

BenzingaNov 15 20:34 · Ratings

H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46

Futu NewsNov 15 19:31 · Ratings

Leerink Partners Maintains ITeos Therapeutics(ITOS.US) With Buy Rating

Futu NewsNov 14 16:33 · Ratings

ITeos Therapeutics Reports Q3 2024 Financial Results

TipRanksNov 14 12:11

Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31

Futu NewsNov 13 19:36 · Ratings